New Study Examines Cannabidiol for Nicotine Use Reduction
A recently published study explored the possibility of using cannabidiol (CBD) to reduce symptoms associated with nicotine withdrawal.
Published earlier this month in the journal Cannabis and Cannabinoid Research, the study called “Cannabidiol Reduces Nicotine Withdrawal Severity and State Anxiety During an Acute E-cigarette Abstinence Period: A Novel, Open-Label Study,” tested the addition of cannabidiol (CBD) in nicotine withdrawal efforts (1). Noting the lack of prior research on nicotine use intervention strategies, the study tested the addition of 320mg of CBD administered to 20 daily nicotine users to test the hypothesis that CBD could reduce the intensity of withdrawal symptoms and anxiety (1).
“After controlling for participants' positive CBD expectancies, results were consistent with hypotheses, suggesting CBD reduced both nicotine withdrawal symptom severity and state anxiety during e-cigarette abstinence,” read the results section (1). “Cannabidiol (CBD) has potential to facilitate e-cigarette quit attempts by decreasing withdrawal symptom intensity and anxiety during nicotine e-cigarette abstinence.”
“These preliminary findings suggest testing the impact of CBD on e-cigarette cessation attempts is warranted,” the authors concluded, noting that 8.1 million adults in the US use e-cigarettes (1).
Reference
- Gournay, L. R.; Petry, J.; Bilsky, S.; Hill, M. A.; Feldner, M.; Peters, E.; Bonn-Miller, M.; Leen-Feldner, E. Cannabidiol reduces nicotine withdrawal severity and state anxiety during an acute e-cigarette abstinence period: A novel, open-label study. Cannabis and Cannabinoid Research 2023 DOI: 10.1089/can.2022.0317.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
